

# E Premkumar Reddy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2714305/publications.pdf>

Version: 2024-02-01

33  
papers

1,708  
citations

623734

14  
h-index

501196

28  
g-index

34  
all docs

34  
docs citations

34  
times ranked

3785  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. <i>Molecular Cancer</i> , 2021, 20, 85.	19.2	23
2	Abstract 1578: Heating it up: Targeting RAS/RAF/PI3K pathway to make melanoma tumors â€˜immunologically hot' and suitable for checkpoint blockade immunotherapies. <i>Cancer Research</i> , 2021, 81, 1578-1578.	0.9	1
3	Simultaneous CK2/TNFK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease. <i>Nature Communications</i> , 2021, 12, 4671.	12.8	28
4	Combination of Ras Modulator and Azacitidine Impacts Innate Immune Signaling Pathway in MDS-L Cell Line. <i>Blood</i> , 2021, 138, 4325-4325.	1.4	0
5	Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression. <i>Pharmaceutics</i> , 2021, 13, 2109.	4.5	3
6	A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent. <i>Molecular Cell</i> , 2020, 79, 180-190.e4.	9.7	14
7	Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
8	Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia. <i>Oncotarget</i> , 2019, 10, 1932-1942.	1.8	4
9	The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/ $\beta$ -Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 4231-4231.	1.4	0
10	Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia. <i>Oncotarget</i> , 2018, 9, 37753-37765.	1.8	8
11	Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 5500-5500.	1.4	0
12	Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. <i>Cell Stem Cell</i> , 2017, 20, 315-328.e7.	11.1	114
13	Drugging the 'undruggable' cancer targets. <i>Nature Reviews Cancer</i> , 2017, 17, 502-508.	28.4	620
14	JNK-signaling: A multiplexing hub in programmed cell death. <i>Genes and Cancer</i> , 2017, 8, 682-694.	1.9	271
15	Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. <i>Oncotarget</i> , 2016, 7, 72845-72859.	1.8	13
16	A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. <i>Cell</i> , 2016, 165, 643-655.	28.9	228
17	Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. <i>Cancer Research</i> , 2016, 76, 1225-1236.	0.9	25
18	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 521-544.	3.0	21

#	ARTICLE	IF	CITATIONS
19	Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. <i>Leukemia</i> , 2016, 30, 86-93.	7.2	22
20	Rigosertib (RIG) in combination with azacitidine (AZA) to modulate epigenetic effects and to overcome clinical resistance to hypomethylating agents (HMA) in myelodysplastic syndromes (MDS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7020-7020.	1.6	3
21	Angiotensin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations. <i>Oncotarget</i> , 2016, 7, 28765-28782.	1.8	43
22	JNK-associated Leucine Zipper Protein Functions as a Docking Platform for Polo-like Kinase 1 and Regulation of the Associating Transcription Factor Forkhead Box Protein K1. <i>Journal of Biological Chemistry</i> , 2015, 290, 29617-29628.	3.4	9
23	Rigosertib Is a More Effective Radiosensitizer Than Cisplatin in Concurrent Chemoradiation Treatment of Cervical Carcinoma, In Vitro and In Vivo. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1180-1187.	0.8	24
24	Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition. <i>Blood</i> , 2014, 124, 3445-3445.	1.4	9
25	Rigosertib Blocks RAS Signaling By Acting As a Small Molecule RAS Mimetic That Binds to the RAS-Binding Domains of RAS Effector Proteins. <i>Blood</i> , 2014, 124, 5616-5616.	1.4	3
26	Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents. <i>Blood</i> , 2013, 122, 1527-1527.	1.4	1
27	The Ins and Outs of Bcr-Abl Inhibition. <i>Genes and Cancer</i> , 2012, 3, 447-454.	1.9	93
28	A Role for the Epidermal Growth Factor Receptor Signaling in Development of Intestinal Serrated Polyps in Mice and Humans. <i>Gastroenterology</i> , 2012, 143, 730-740.	1.3	32
29	Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study. <i>Blood</i> , 2012, 120, 3794-3794.	1.4	4
30	Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (E)-2-[2-Methoxy-5-[(2,4,6-trimethoxystyrylsulfonyl)methyl]phenylamino]acetate (ON 01910.Na); Synthesis, Structure-Activity Relationship, and Biological Activity. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6254-6276.	6.4	84
31	An In Vivo Functional Screen Identifies miRNA-150 As a Regulator of Hematopoietic Regeneration Post Chemotherapeutic Injury. <i>Blood</i> , 2011, 118, 2333-2333.	1.4	6
32	Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study. <i>Blood</i> , 2010, 116, 2944-2944.	1.4	2
33	Synergistic Effects of a Novel Water-Soluble Small Molecule, ON 013105, and Rituximab on Mantle Cell Lymphoma In Vitro and In Vivo. <i>Blood</i> , 2010, 116, 771-771.	1.4	0